Pimavanserin - ACADIA Pharmaceuticals

Drug Profile

Pimavanserin - ACADIA Pharmaceuticals

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antiparkinsonians; Antipsychotics; Piperidines; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Schizophrenia
  • Phase II Agitation; Major depressive disorder
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Insomnia

Most Recent Events

  • 03 Nov 2017 Efficacy and adverse events data from the phase II Study 019 released by Acadia Pharmaceuticals
  • 05 Oct 2017 Phase-III clinical trials in Schizophrenia (Adjunctive treatment, Treatment-experienced) in Germany (PO) (EudraCT2016-003437-18)
  • 04 Oct 2017 Pimavanserin receives Breakthrough Therapy status for Psychotic disorders (Dementia-associated psychosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top